A5061891789- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Lung Cancer Diagnosis and Treatment
- Sarcoma Diagnosis and Treatment
- Lung Cancer Research Studies
- Breast Cancer Treatment Studies
- Testicular diseases and treatments
- Multiple and Secondary Primary Cancers
- Cancer Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Cancer therapeutics and mechanisms
- Metastasis and carcinoma case studies
- Advanced Radiotherapy Techniques
- Chemotherapy-induced organ toxicity mitigation
- Cancer Research and Treatments
- Genetic factors in colorectal cancer
- Advances in Oncology and Radiotherapy
- Radiopharmaceutical Chemistry and Applications
- Melanoma and MAPK Pathways
- Peptidase Inhibition and Analysis
- Chemotherapy-related skin toxicity
- Medical Imaging Techniques and Applications
- HER2/EGFR in Cancer Research
German Cancer Research Center
1997-2022
Heidelberg University
1997-2022
Essen University Hospital
2004-2007
University of Duisburg-Essen
1995-2006
Novartis (Germany)
2004-2005
Merck (Germany)
2004-2005
Marienkrankenhaus Hamburg
2005
Bayer (Germany)
2004
Klinik und Poliklinik für Urologie
1984-2004
Bayer (United States)
2004
3605 Background: Vascular endothelial growth factors (VEGF-A, -B, -C, D and -E) are potent angiogenesis secreted by many solid tumors. PTK/ZK is a novel, oral, small molecule inhibitor that blocks all known VEGF receptor tyrosine kinases, important mediators in the formation of new blood lymph vessels contribute to tumor metastasis. Method: The goal this trial determine maximum tolerated dose (MTD) dose-limiting toxicities (DLTs) once-daily oral combination with infusional 5-fluorouracil...
Purpose. Improvements in image-guided radiotherapy (IGRT) enable accurate and precise treatment of moving tumors the abdomen while simultaneously sparing healthy tissue. However, lack validation tools for newly developed MR-guided hybrid devices such as MR-Linac is an open issue. This study presents a custom abdominal phantom with respiratory organ motion multimodal imaging contrast to perform end-to-end tests IGRT planning scenarios.Methods. The contains deformable anatomically shaped liver...
3049 Background:BAY 43–9006 (BAY) is a novel signal transduction inhibitor that prevents tumor cell proliferation and angiogenesis through blockade of the Raf/MEK/ERK pathway at level Raf kinase receptor tyrosine kinases VEGFR-2 PDGFR-β. Previous single-agent phase I studies show BAY well tolerated, with manageable reversible side effects, most commonly hand-foot skin (HFS) reaction, rash, fatigue, diarrhea. This study was initiated to determine safety pharmacokinetics (PK) in combination...
3018 Background: Growth factor signaling through EGFR drives tumor proliferation, motility, angiogenic stimulation, and protects the cells from stress induced apoptosis. EMD 72000 is a humanized monoclonal anti-EGFR IgG1 antibody that blocks ligand binding, signaling, induces receptor downregulation, potentially participates in antibody-dependent cell-mediated cell killing. Methods: A phase I study was conducted to assess safety anti-tumor activity of 24 patients with advanced refractory...
3558 Background: Increased angiogenesis is correlated with poor prognosis in patients advanced metastatic colorectal cancer (CRC). PTK/ZK a novel, oral inhibitor that potently inhibits all known VEGF receptor tyrosine kinases, important mediators the formation of new blood vessels contribute to tumor growth and metastasis. Methods: This trial determined MTD DLTs once-daily combination infusional 5-fluorouracil (5-FU)/leucovorin (LV) plus irinotecan (FOLFIRI) as first-line treatment CRC. was...
3558 Background: Increased angiogenesis is correlated with poor prognosis in patients advanced metastatic colorectal cancer (CRC). PTK/ZK a novel, oral inhibitor that potently inhibits all known VEGF receptor tyrosine kinases, important mediators the formation of new blood vessels contribute to tumor growth and metastasis. Methods: This trial determined MTD DLTs once-daily combination infusional 5-fluorouracil (5-FU)/leucovorin (LV) plus irinotecan (FOLFIRI) as first-line treatment CRC. was...
3156 Background: EG cancer is diagnosed in more than 60% of patients (pts) a locally advanced or metastatic stage. In this situation treatment options are limited; therefore exploration new therapeutic regimen warranted. EGFR expressed high proportion gastric cancers associated with poor prognosis. Matuzumab, humanized monoclonal anti-EGFR IgG1 antibody, inhibits ligand-mediated receptor signalling and has demonstrated antitumor activity solid tumors. phase I study we evaluated the safety,...
Between 1968 and 1979, a total of 271 patients with advanced Hodgkin's disease received as first systemic chemotherapy MOPP (mechlorethamine [nitrogen mustard], oncovin [vincristine], procarbazine prednisone) or COPP (as above, but cyclophosphamide instead nitrogen mustard). In 162 the (60%) full remission was achieved. Demonstration signs, bioptically confirmed bone-marrow infiltration suboptimal cytostatic dosage correlated significantly lower full-remission rate. A significant trend...
Combined treatment with adriamycin, cyclophosphamide and vincristine (ACO) was used in 50 out-patients histologically verified small-cell bronchial carcinoma. In 26 patients locally regionally limited metastases ("limited disease") radiotherapy (3000 rad focal dose) to mediastinum, hili tumour opacity as well prophylactic cranial irradiation were performed after 3 cycles of chemotherapy. Complete clinical remission (without endoscopic control) achieved 32 out patients. Remissions bilateral...
3056 Background:BAY 43–9006 (BAY) is a novel signal transduction inhibitor that prevents tumor cell proliferation and angiogenesis through blockade of the Raf/MEK/ERK pathway at level Raf kinase receptor tyrosine kinases VEGFR-2 PDGFR-β. Previous single-agent phase I trials show BAY well tolerated with manageable reversible side effects, most commonly hand-foot skin (HFS) reaction, rash, fatigue, diarrhea. This study was initiated to determine safety pharmacokinetics (PK) in combination...
3018 Background: Growth factor signaling through EGFR drives tumor proliferation, motility, angiogenic stimulation, and protects the cells from stress induced apoptosis. EMD 72000 is a humanized monoclonal anti-EGFR IgG1 antibody that blocks ligand binding, signaling, induces receptor downregulation, potentially participates in antibody-dependent cell-mediated cell killing. Methods: A phase I study was conducted to assess safety anti-tumor activity of 24 patients with advanced refractory...